Developing a new treatment for COVID-19
Official title: DEVELOPMENT OF A COMPOUND FOR THE TREATMENT OF COVID-19
Funded at Aligos Therapeutics, INC. · NIH-10933185 · Data updated 2026-11-12
This study is testing a new antiviral medication aimed at helping people with COVID-19, and it will involve patients to see how well the treatment works and how safe it is.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aligos Therapeutics, INC. NIH-funded |
| Lab location | 1 site (South San Francisco, United States) |
| Project start | September 22, 2023 |
| Project end | February 15, 2026 |
| Funding year | 2023 |
| Award (this year) | $8,469,477 |
| NIH project number | 75N93023C00052-0-9999-1 |
| Project ID | NIH-10933185 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals diagnosed with COVID-19 who are seeking new treatment options.
✕Less likely to help
Patients who are not currently infected with COVID-19 or those who have already recovered may not benefit from this research.
What this research studies
This research focuses on creating a new antiviral medication specifically designed to combat COVID-19. It involves a series of advanced development activities, including optimizing the chemical composition of the drug, ensuring it can be manufactured safely and effectively, and conducting thorough assessments of its safety and efficacy in clinical settings. Patients may be involved in trials to evaluate how well this new treatment works against the virus. The goal is to progress this therapeutic candidate through the necessary stages to make it available for public use.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment option for COVID-19 patients.
How similar studies have gone: Previous research has shown promise in developing antiviral treatments for COVID-19, indicating that this approach has potential for success.
Where this research is happening
-
Aligos Therapeutics, INC.
South San Francisco, United States Active
Researchers
- Principal investigator: Wang, Stanley — Aligos Therapeutics, INC.
- Study coordinator: Wang, Stanley
Related research
Other NIH-funded projects on the same topics.
-
Structural factors linking minimum wage, COVID-19, and community violence
A long-term study will explore whether higher minimum wages and pandemic-related economic factors are connected to changes in violence in US communities.
-
COVID-19 healthcare disruptions and heart health inequities in NYC adults with multiple conditions
This project looks at how COVID-19-related gaps in care affected heart health in adults with several chronic conditions in New York City.
-
Modifying body fat to aid COVID-19 recovery through behavioral strategies
A study in veterans explores whether changing weight through lifestyle habits can improve recovery after COVID-19–related health problems.
-
Post-COVID Neuro-Cognitive Changes in Older African Americans
A study explores how COVID-19 affects thinking, memory, and daily life in older African American adults and what might be driving these changes.
-
How COVID school closures affected kids with or at risk for developmental differences
This NIH grant follows children aged 4 to 15 and their families to see how pandemic school closures impacted emotional well-being and parenting over three years.
-
Long-term COVID-19 effects in older Veterans and a rehabilitation approach
This project looks at how COVID-19 affects blood vessel health in older Veterans and tests a rehab strategy together with a mitochondria-targeted antioxidant to help recovery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.